Dalzanemdor Halted for Alzheimer’s, Fails to Boost Cognitive Function

Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in patients with mild cognitive impairment or mild dementia. In the LIGHTWAVE study (NCT05619692), patients treated with dalzanemdor didn’t show significant improvement in cognitive function, as measured by the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test, compared with those on a placebo, though the treatment was shown to be safe and well tolerated.